Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Aug 2022
Novavax submits application to the U.S. FDA for emergency use authorisation for Novavax COVID-19 vaccine, adjuvanted as a booster in adults aged 18 and older
15 August 2022 - If authorised, Novavax' vaccine would be the first protein-based COVID-19 booster for adults. ...
Posted by Michael Wonder on 15 Aug 2022
A doctor says a patient saved over $1,000 a month by ordering prescriptions through Mark Cuban’s online pharmacy
14 August 2022 - Deena Kishawi, an OB-GYN resident physician in Chicago, was reviewing the medication of one of her patients ...
Posted by Michael Wonder on 15 Aug 2022
argenx announces European Commission approval of Vyvgart (efgartigimod alfa-fcab) for the treatment of generalised myasthenia gravis
11 August 2022 - Vyvgart is the first neonatal Fc receptor blocker approved in Europe for the treatment of adults living ...
Posted by Michael Wonder on 15 Aug 2022
Calls for decision on Trikafta as new advice shows health system savings and decades more life for patients
15 August 2022 - Pressure is mounting on the Government to make a decision on whether it will fund the ...
Posted by Michael Wonder on 15 Aug 2022
ATAGI recommends COVID-19 vaccine use in some children aged 6 months to 4 years
12 August 2022 - From 5 September 2022, the Australian Technical Advisory Group on Immunisation recommends COVID-19 vaccination for children aged ...
Posted by Michael Wonder on 15 Aug 2022
PHARMAC shares update on its assessment of Trikafta
15 August 2022 - PHARMAC has today published the latest record of advice from PTAC and, for the first time, has ...
Posted by Michael Wonder on 14 Aug 2022
Economic cost and sustainability of oral therapies in precision oncology
12 August 2022 - Precision oncology promises improved outcomes but the cost effectiveness and accessibility of targeted therapies is debatable. ...
Posted by Michael Wonder on 14 Aug 2022
Revealed: sick state of bulk-billing
15 August 2022 - Doctors expect the national bulk-billing rate may plunge to as little as 30% within two years ...
Posted by Michael Wonder on 14 Aug 2022
FDA approves first medicine under new Project Optimus
12 August 2022 - Project Optimus is another initiative of the FDA Oncology Center of Excellence. ...
Posted by Michael Wonder on 13 Aug 2022
Restrictions put on diabetes drug Ozempic leave users feeling ‘fat shamed’
13 August 2022 - A drug that caused a buzz for its ability to help people shed kilos has now been ...
Posted by Michael Wonder on 13 Aug 2022
Patients avoid paying hundreds of dollars in out-of-pocket fees after Ramsay and Bupa end stalemate
12 August 2022 - The eleventh hour peace deal will avoid Bupa customers paying potentially hundreds of dollars in out of ...
Posted by Michael Wonder on 13 Aug 2022
FDA approves first NGS based companion diagnostic to aid in selecting non-small-cell lung cancer patients with HER2 (ERBB2) activating mutations (SNVs & exon 20 insertions) for treatment with Enhertu
12 August 2022 - This approval marks the Oncomine Dx Target Test’s eighth companion diagnostic therapy selection indication ...
Posted by Michael Wonder on 12 Aug 2022
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone linked ECG device
12 August 2022 - It is the first recommendation to be issued by NICE’s diagnostics advisory committee via its Early Value ...
Posted by Michael Wonder on 12 Aug 2022
Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld
12 August 2022 - Half a million people in the UK with conditions like blood cancer that prevents them being ...
Posted by Michael Wonder on 12 Aug 2022
US move to negotiate drug prices a rare defeat for big pharma
12 August 2022 - Big pharma spent more than any other industry to lobby Congress and federal agencies this year, ...